Items where Funder is Capella Bioscience Ltd.

NOEXT REF GIVEN

Ross, R, Corinaldesi, C, Migneco, G et al. (5 more authors) (2019) BDCA2 Targeting of Human Plasmacytoid Dendritic Cells via CBS004 Reverts Dependent IFN Activation and Tissue Fibrosis in vitro and in vivo. In: 2019 ACR/ARP Annual Meeting, 08-13 Nov 2019, Atlanta, Georgia, USA.

Corinaldesi, C, El-Sherbiny, YM, Migneco, G et al. (4 more authors) (2018) CBS004, a Novel Monoclonal Antibody Against Bdca-2 Inhibits TLR-Induced Activation of Human pDC in Vitro and In Vivo. a Novel Therapeutic Target for Systemic Sclerosis. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL. Wiley .